Functional signatures identified in B-cell non-Hodgkin lymphoma profiles-Reference-Cited by-同舟云学术

Functional signatures identified in B-cell non-Hodgkin lymphoma profiles

Published:2009-01 Issue:10 Volume:50 Page:1699-1708
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Aggarwal Mohit,Sánchez-Beato Margarita,Aggarwal Mohit,Sánchez-Beato Margarita,Gómez-López Gonzalo,Al-Shahrour Fátima,Martínez Nerea,Rodríguez Antonia,Ruiz-Ballesteros Elena,Camacho Francisca I.,Pérez-Rosado Alberto,de la Cueva Paloma,Artiga María J.,Pisano David G.,Kimby Eva,Dopazo Joaquín,Villuendas Raquel,Piris Miguel A.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.1080/10428190903189035

Reference61 articles.

1. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response

2. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

3. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

4. Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mutations in the transcription factor FOXO1 mimic positive selection signals to promote germinal center B cell expansion and lymphomagenesis;Immunity;2021-08

2. Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma;Scientific Reports;2021-01-21

3. Two distinct molecular subtypes of chronic lymphocytic leukemia give new insights on the pathogenesis of the disease and identify novel therapeutic targets;Leukemia & Lymphoma;2015-05-12

4. Splenic marginal zone lymphoma: comprehensive analysis of gene expression and miRNA profiling;Modern Pathology;2013-02-22

5. A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma;British Journal of Haematology;2012-08-04